MMSE at 18 months Model 1 (R=0.564, adj-R2=0.265. Adj-R2 was increased by 0.124 with FDG) | MMSE at 18 months Model 2 (R=0.642, adj-R2=0.325. Adj-R2 was increased by 0.055 with FDG) | MoCA at 18 months Model 1 (R=0.767, adj-R2=0.553. Adj-R2 was increased by 0.071 with FDG) | MoCA at 18 months Model 2 (R=0.798, adj-R2=0.578. Adj-R2 was increased by 0.065 with FDG) | |
---|---|---|---|---|
MMSE baseline | 0.33 (0.11) p=0.005 | 0.22 (0.11) p=0.057 | – | – |
MoCA baseline | – | – | 0.65 (0.09) p<0.001 | 0.61 (0.10) p<0.001 |
FDG parietal/cerebellum | 0.38 (0.11) p=0.001 | 0.28 (0.11) p=0.016 | 0.30 (0.09) p=0.002 | 0.29 (0.09) p=0.003 |
Age at baseline | −0.05 (0.11) p=0.7 | 0.02 (0.11) p=0.9 | −0.07 (0.09) p=0.5 | −0.09 (0.09) p=0.4 |
Female | 0.02 (0.11) p=0.9 | 0.06 (0.11) p=0.6 | 0.03 (0.09) p=0.8 | −0.01 (0.09) p=0.9 |
Years education | 0.04 (0.10) p=0.7 | −0.08 (0.11) p=0.9 | −0.14 (0.09) p=0.1 | −0.14 (0.09) p=0.12 |
Disease duration baseline | – | −0.02 (0.10) p=0.9 | – | 0.00 (0.10) p=0.9 |
LEDD baseline | – | −0.09 (0.09) p=0.4 | – | 0.18 (0.09) p=0.048 |
UPDRS III baseline | – | −0.05 (0.10) p=0.6 | – | 0.11 (0.09) p=0.2 |
PD-MCI baseline | – | −0.33 (0.12) p=0.007 | – | −0.17 (0.11) p=0.13 |
Values are β (SE).
Adj, adjusted; LEDD, levodopa equivalent daily dose; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; PD-MCI, Parkinson's disease-mild cognitive impairment; UPDRS III, motor subsection of Unified Parkinson's Disease Rating Scale.